The demand for GLP-1 drugs (like Wegovy and several others) continues to grow. Despite this escalating demand, the prices for some of these popular drugs are actually dropping, according to a new report from the U.S. Department of Health and Human Services (HHS). However, there's one major question: will consumers actually feel the benefits of these decent price drops?

GLP-1s are popular medications, most of which are prescribed for patients with Type 2 diabetes. Wegovy is also approved to decrease the risk of serious heart problems such as heart attacks. Saxenda, Wegovy, and Zepbound have all been approved for weight loss. Guidance from the Centers for Medicare and Medicaid Services allows Part D plans to cover anti-obesity medications if they are approved for additional health benefits and used for those conditions.

Last year, the American healthcare industry spent $38.6 billion on semaglutide (Ozempic, Wegovy, Rybelsus), and $13.2 billion on tirzepatide (Mounjaro, Zepbound). Compared to 2022, these were increases of 100.1% and 373.1%, respectively.